Association of claudin 18.2 expression with outcomes of ramucirumab plus paclitaxel as second-line therapy in advanced gastric cancer

Figure 1 Overall survival according to claudin 18. 2 status and multivariable Cox regression analysis for overall survival. A: Overall survival (OS) according to claudin 18.2 (CLDN18.2) status. Kaplan-Meier curves for OS in patients with advanced gastric cancer treated with ramucirumab plus paclitaxel, stratified by CLDN18.2 status. Median OS was 11.4 months in the CLDN18.2-negative group and 10.4 months in the CLDN18.2-positive group. The proportional hazards assumption was violated; therefore, restricted mean survival time analysis was additionally performed; B: Multivariable Cox regression analysis for OS. Forest plot showing adjusted hazard ratios for OS in the multivariable Cox proportional hazards model including age, Eastern Cooperative Oncology Group performance status, human epidermal growth factor receptor 2 positivity, and the presence of liver and peritoneal metastases. CLDN18.2 expression was not independently associated with OS. CLDN18.2: Claudin 18.2; ECOG: Eastern Cooperative Oncology Group; HER2: Human epidermal growth factor receptor 2.